{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:33:59Z","timestamp":1793738039235,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T00:00:00Z","timestamp":1675555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82125037"],"award-info":[{"award-number":["82125037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinically, activated EGFR mutation associated chemo-drugs resistance has severely threaten NSCLC patients. Nanoparticle based small interfering RNA (siRNA) therapy representing another promising alternative by silencing specific gene while still suffered from charge associated toxicity, strong immunogenicity and poor targetability. Herein, we reported a novel EGFR-mutant NSCLC therapy relying on edible and cation-free kiwi-derived extracellular vesicles (KEVs), which showed sevenfold enhancement of safe dosage compared with widely used cationic liposomes and could be further loaded with Signal Transducer and Activator of Transcription 3 interfering RNA (siSTAT3). siSTAT3 loaded KEVs (STAT3\/KEVs) could be easily endowed with EGFR targeting ability (STAT3\/EKEVs) and fluorescence by surface modification with tailor-making aptamer through hydrophobic interaction. STAT3\/EKEVs with a controlled size of 186\u00a0nm displayed excellent stability, high specificity and good cytotoxicity towards EGFR over-expressing and mutant PC9-GR4-AZD1 cells. Intriguingly, the systemic administration of STAT3\/EKEVs significantly suppressed subcutaneous PC9-GR4-AZD1 tumor xenografts in nude mice by STAT3 mediated apoptosis. This safe and robust KEVs has emerged as the next generation of gene delivery platform for NSCLC therapy after multiple drug-resistance.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1186\/s12951-023-01766-w","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T13:03:09Z","timestamp":1675602189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Haoying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongpei","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,5]]},"reference":[{"key":"1766_CR1","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.3390\/ijms21176329","volume":"21","author":"A Friedlaender","year":"2020","unstructured":"Friedlaender A, Addeo A, Russo A, Gregorc V, Cortinovis D, Rolfo CD. Targeted therapies in early stage NSCLC: hype or hope? Int J Mol Sci. 2020;21:6329.","journal-title":"Int J Mol Sci"},{"key":"1766_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1766_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535\u201346.","journal-title":"Nat Rev Cancer"},{"key":"1766_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7150\/ijbs.22955","volume":"14","author":"Z Yang","year":"2018","unstructured":"Yang Z, Tam KY. Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci. 2018;14:204\u201316.","journal-title":"Int J Biol Sci"},{"key":"1766_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","volume":"19","author":"S Boumahdi","year":"2020","unstructured":"Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19:39\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"1766_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15212\/AMM-2022-1001","volume":"1","author":"H Li","year":"2022","unstructured":"Li H, Wei W, Xu H. Drug discovery is an eternal challenge for the biomedical sciences. Acta Materia Medica. 2022;1:1\u20133.","journal-title":"Acta Materia Medica"},{"key":"1766_CR7","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/s41467-019-09734-5","volume":"10","author":"J Bertran-Alamillo","year":"2019","unstructured":"Bertran-Alamillo J, Cattan V, Schoumacher M, Codony-Servat J, Gim\u00e9nez-Capit\u00e1n A, Cantero F, Burbridge M, Rodr\u00edguez S, Teixid\u00f3 C, Roman R, Castellv\u00ed J, et al. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. Nat Commun. 2019;10:1812.","journal-title":"Nat Commun"},{"key":"1766_CR8","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.3389\/fimmu.2019.03135","volume":"10","author":"A Nigro","year":"2019","unstructured":"Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi MA, Montico B, Triggiani M, Pepe S, Stellato C, Casolaro V, et al. Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC. Front Immunol. 2019;10:3135.","journal-title":"Front Immunol"},{"key":"1766_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1042\/CS20200039","volume":"134","author":"J Fan","year":"2020","unstructured":"Fan J, Xu G, Chang Z, Zhu L, Yao J. miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2\/STAT3 pathway. Clin Sci. 2020;134:807\u201325.","journal-title":"Clin Sci"},{"key":"1766_CR10","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7150\/thno.49600","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, et al. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021;11:824\u201340.","journal-title":"Theranostics"},{"key":"1766_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207\u201321.","journal-title":"Cancer Cell"},{"key":"1766_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3390\/cancers12051107","volume":"12","author":"J Mohrherr","year":"2020","unstructured":"Mohrherr J, Uras IZ, Moll HP, Casanova E. STAT3: versatile functions in non-small cell lung cancer. Cancers. 2020;12:1107.","journal-title":"Cancers"},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.7150\/thno.9404","volume":"4","author":"MS Draz","year":"2014","unstructured":"Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC, Gray JW, Chen FF. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics. 2014;4:872\u201392.","journal-title":"Theranostics"},{"key":"1766_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81:389\u201395.","journal-title":"Drugs"},{"key":"1766_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Lik Yuen Chan H, Yoon KT, Klinker H, Manns M, Petersen J, et al. RNA interference therapy with ARC-520 results in prolonged hepatitis b surface antigen response in patients with chronic hepatitis B infection. Hepatology. 2020;72:19\u201331.","journal-title":"Hepatology"},{"key":"1766_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9647","author":"S Alidori","year":"2016","unstructured":"Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aac9647.","journal-title":"Sci Transl Med"},{"key":"1766_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/molecules23071586","volume":"23","author":"Y Lu","year":"2018","unstructured":"Lu Y, Li J, Su N, Lu D. The mechanism for siRNA transmembrane assisted by PMAL. Molecules. 2018;23:1586.","journal-title":"Molecules"},{"key":"1766_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jconrel.2017.02.019","volume":"259","author":"AE Arnold","year":"2017","unstructured":"Arnold AE, Czupiel P, Shoichet M. Engineered polymeric nanoparticles to guide the cellular internalization and trafficking of small interfering ribonucleic acids. J Control Release. 2017;259:3\u201315.","journal-title":"J Control Release"},{"key":"1766_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trsl.2019.07.006","volume":"214","author":"MA Subhan","year":"2019","unstructured":"Subhan MA, Torchilin VP. Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res. 2019;214:62\u201391.","journal-title":"Transl Res"},{"key":"1766_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.addr.2015.12.004","volume":"104","author":"J Park","year":"2016","unstructured":"Park J, Park J, Pei Y, Xu J, Yeo Y. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev. 2016;104:93\u2013109.","journal-title":"Adv Drug Deliv Rev"},{"key":"1766_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","volume":"9","author":"S Barua","year":"2014","unstructured":"Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today. 2014;9:223\u201343.","journal-title":"Nano Today"},{"key":"1766_CR22","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.addr.2013.09.019","volume":"65","author":"JL Markman","year":"2013","unstructured":"Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013;65:1866\u201379.","journal-title":"Adv Drug Deliv Rev"},{"key":"1766_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","volume":"10","author":"NB Charbe","year":"2020","unstructured":"Charbe NB, Amnerkar ND, Ramesh B, Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R, Satija S, Metha M, Chellappan DK, et al. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020;10:2075\u2013109.","journal-title":"Acta Pharm Sin B"},{"key":"1766_CR24","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.3390\/molecules25112692","volume":"25","author":"F Mainini","year":"2020","unstructured":"Mainini F, Eccles MR. Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25:2692.","journal-title":"Molecules"},{"key":"1766_CR25","doi-asserted-by":"publisher","first-page":"102239","DOI":"10.1016\/j.nano.2020.102239","volume":"29","author":"MA Subhan","year":"2020","unstructured":"Subhan MA, Torchilin VP. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine. 2020;29:102239.","journal-title":"Nanomedicine"},{"key":"1766_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, et al. The onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14:1084\u20137.","journal-title":"Nat Nanotechnol"},{"key":"1766_CR27","doi-asserted-by":"publisher","first-page":"e2104779","DOI":"10.1002\/adma.202104779","volume":"33","author":"T Jiang","year":"2021","unstructured":"Jiang T, Qiao Y, Ruan W, Zhang D, Yang Q, Wang G, Chen Q, Zhu F, Yin J, Zou Y, Qian R, et al. Cation-free sirna micelles as effective drug delivery platform and potent RNAI nanomedicines for glioblastoma therapy. Adv Mater. 2021;33:e2104779.","journal-title":"Adv Mater"},{"key":"1766_CR28","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","volume":"111","author":"JE Zuckerman","year":"2014","unstructured":"Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, Chmielowski B, Ribas A, Davis ME, Yen Y. Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA. 2014;111:11449\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1766_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41587-020-0725-7","volume":"38","author":"M Zipkin","year":"2020","unstructured":"Zipkin M. Big pharma buys into exosomes for drug delivery. Nat Biotechnol. 2020;38:1226\u20138.","journal-title":"Nat Biotechnol"},{"key":"1766_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55:2\u201312.","journal-title":"Acc Chem Res"},{"key":"1766_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jconrel.2018.02.015","volume":"275","author":"M Merino","year":"2018","unstructured":"Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology: state of the art and future perspectives. J Control Release. 2018;275:162\u201376.","journal-title":"J Control Release"},{"key":"1766_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2019.04.025","volume":"303","author":"N Wang","year":"2019","unstructured":"Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J Control Release. 2019;303:130\u201350.","journal-title":"J Control Release"},{"key":"1766_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/nano10020190","volume":"10","author":"CT Inglut","year":"2020","unstructured":"Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, Huang HC. Immunological and toxicological considerations for the design of liposomes. Nanomaterials. 2020;10:190.","journal-title":"Nanomaterials"},{"key":"1766_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/pharmaceutics13040498","volume":"13","author":"M Alfieri","year":"2021","unstructured":"Alfieri M, Leone A, Ambrosone A. Plant-derived nano and microvesicles for human health and therapeutic potential in nanomedicine. Pharmaceutics. 2021;13:498.","journal-title":"Pharmaceutics"},{"key":"1766_CR35","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.3390\/ijms22105366","volume":"22","author":"O Urz\u00ec","year":"2021","unstructured":"Urz\u00ec O, Raimondo S, Alessandro R. Extracellular vesicles from plants: current knowledge and open questions. Int J Mol Sci. 2021;22:5366.","journal-title":"Int J Mol Sci"},{"key":"1766_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/ijms23010191","volume":"23","author":"T Karamanidou","year":"2021","unstructured":"Karamanidou T, Tsouknidas A. Plant-derived extracellular vesicles as therapeutic nanocarriers. Int J Mol Sci. 2021;23:191.","journal-title":"Int J Mol Sci"},{"key":"1766_CR37","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/ncomms2886","volume":"4","author":"Q Wang","year":"2013","unstructured":"Wang Q, Zhuang X, Mu J, Deng ZB, Jiang H, Zhang L, Xiang X, Wang B, Yan J, Miller D, Zhang HG. Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. Nat Commun. 2013;4:1867.","journal-title":"Nat Commun"},{"key":"1766_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.biomaterials.2016.06.018","volume":"101","author":"M Zhang","year":"2016","unstructured":"Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321\u201340.","journal-title":"Biomaterials"},{"key":"1766_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/mt.2013.64","volume":"21","author":"S Ju","year":"2013","unstructured":"Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B, Zhang L, Roth M, et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol Ther. 2013;21:1345\u201357.","journal-title":"Mol Ther"},{"key":"1766_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jprot.2017.11.017","volume":"173","author":"S Raimondo","year":"2018","unstructured":"Raimondo S, Saieva L, Cristaldi M, Monteleone F, Fontana S, Alessandro R. Label-free quantitative proteomic profiling of colon cancer cells identifies acetyl-CoA carboxylase alpha as antitumor target of citrus limon-derived nanovesicles. J Proteomics. 2018;173:1\u201311.","journal-title":"J Proteomics"},{"key":"1766_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0378-8741(02)00125-3","volume":"81","author":"N Motohashi","year":"2002","unstructured":"Motohashi N, Shirataki Y, Kawase M, Tani S, Sakagami H, Satoh K, Kurihara T, Nakashima H, Mucsi I, Varga A, Moln\u00e1r J. Cancer prevention and therapy with kiwifruit in Chinese folklore medicine: a study of kiwifruit extracts. J Ethnopharmacol. 2002;81:357\u201364.","journal-title":"J Ethnopharmacol"},{"key":"1766_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/01635581.2019.1650190","volume":"72","author":"G Lippi","year":"2020","unstructured":"Lippi G, Mattiuzzi C. Kiwifruit and cancer: an overview of biological evidence. Nutr Cancer. 2020;72:547\u201353.","journal-title":"Nutr Cancer"},{"key":"1766_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12032-021-01465-2","volume":"38","author":"L Kou","year":"2021","unstructured":"Kou L, Zhu Z, Redington C, Bai Q, Wakefield M, Lequio M, Fang Y. Potential use of kiwifruit extract for treatment of melanoma. Med Oncol. 2021;38:25.","journal-title":"Med Oncol"},{"key":"1766_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s40425-019-0817-4","volume":"7","author":"M Cao","year":"2019","unstructured":"Cao M, Yan H, Han X, Weng L, Wei Q, Sun X, Lu W, Wei Q, Ye J, Cai X, Hu C, et al. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. J Immunother Cancer. 2019;7:326.","journal-title":"J Immunother Cancer"},{"key":"1766_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ymthe.2021.08.028","volume":"30","author":"X Han","year":"2022","unstructured":"Han X, Wei Q, Lv Y, Weng L, Huang H, Wei Q, Li M, Mao Y, Hua D, Cai X, Cao M, et al. Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Mol Ther. 2022;30:327\u201340.","journal-title":"Mol Ther"},{"key":"1766_CR46","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acsnano.0c09681","volume":"15","author":"M Hu","year":"2021","unstructured":"Hu M, Zhang J, Kong L, Yu Y, Hu Q, Yang T, Wang Y, Tu K, Qiao Q, Qin X, Zhang Z. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy. ACS Nano. 2021;15:3123\u201338.","journal-title":"ACS Nano"},{"key":"1766_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2018.09.016","volume":"289","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang L, Hu Y, Jiang K, Li Z, Lin YZ, Wei G, Lu W. Cell-permeable NF-\u03baB inhibitor-conjugated liposomes for treatment of glioma. J Control Release. 2018;289:102\u201313.","journal-title":"J Control Release"},{"key":"1766_CR48","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jconrel.2021.05.024","volume":"335","author":"H Huang","year":"2021","unstructured":"Huang H, Zhang C, Yang S, Xiao W, Zheng Q, Song X. The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. J Control Release. 2021;335:449\u201356.","journal-title":"J Control Release"},{"key":"1766_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biomaterials.2017.02.019","volume":"125","author":"S Persano","year":"2017","unstructured":"Persano S, Guevara ML, Li Z, Mai J, Ferrari M, Pompa PP, Shen H. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017;125:81\u20139.","journal-title":"Biomaterials"},{"key":"1766_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","volume":"66","author":"B Ozpolat","year":"2014","unstructured":"Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110\u20136.","journal-title":"Adv Drug Deliv Rev"},{"key":"1766_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cbi.2017.09.006","volume":"295","author":"K He","year":"2018","unstructured":"He K, Tang M. Safety of novel liposomal drugs for cancer treatment: advances and prospects. Chem Biol Interact. 2018;295:13\u20139.","journal-title":"Chem Biol Interact"},{"key":"1766_CR52","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cell.2020.06.013","volume":"182","author":"MA Gillette","year":"2020","unstructured":"Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, Li Y, Liang WW, Reva B, Krek A, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 2020;182:200-225.e35.","journal-title":"Cell"},{"key":"1766_CR53","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","volume":"126","author":"GA Durm","year":"2020","unstructured":"Durm GA, Jabbour SK, Althouse SK, Liu Z, Sadiq AA, Zon RT, Jalal SI, Kloecker GH, Williamson MJ, Reckamp KL, Langdon RM, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: hoosier cancer research network LUN 14\u2013179. Cancer. 2020;126:4353\u201361.","journal-title":"Cancer"},{"key":"1766_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx014","author":"I Chaib","year":"2017","unstructured":"Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx014.","journal-title":"J Natl Cancer Inst"},{"key":"1766_CR55","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/2159-8290.CD-20-1543","volume":"11","author":"N Pore","year":"2021","unstructured":"Pore N, Wu S, Standifer N, Jure-Kunkel M, de Los Reyes M, Shrestha Y, Halpin R, Rothstein R, Mulgrew K, Blackmore S, Martin P, et al. Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non-small cell lung cancer and is reversed by STAT3 knockdown. Cancer Discov. 2021;11:2828\u201345.","journal-title":"Cancer Discov"},{"key":"1766_CR56","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1158\/1535-7163.MCT-17-1194","volume":"17","author":"C Njatcha","year":"2018","unstructured":"Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. STAT3 cyclic decoy demonstrates robust antitumor effects in non-small cell lung cancer. Mol Cancer Ther. 2018;17:1917\u201326.","journal-title":"Mol Cancer Ther"},{"key":"1766_CR57","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.jid.2016.11.020","volume":"137","author":"A Grada","year":"2017","unstructured":"Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137:e11\u20136.","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01766-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:11:12Z","timestamp":1675703472000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01766-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01766-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,5]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}